Inhibition of cell growth: Effects of the tyrosine kinase inhibitor CGP 53716

Journal of Pharmacology and Experimental Therapeutics

Volumn 283, Issue 1, 1997, Pages 402-410

  Major, Terry C ^a   Keiser, Joan A ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; N [4 METHYL 3 (4 PYRIDIN 3 YLPYRIMIDIN 2 YLAMINO)PHENYL]BENZAMIDE; N [4 METHYL 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]PHENYL]BENZAMIDE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN C FOS; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AUTOPHOSPHORYLATION; BLOOD VESSEL INJURY; CELL GROWTH; CONCENTRATION RESPONSE; CYTOTOXICITY; DNA SYNTHESIS INHIBITION; FIBROBLAST; GROWTH INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SMOOTH MUSCLE FIBER;

3T3 CELLS; ANIMALS; CELL DIVISION; CELLS, CULTURED; DNA; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; GROWTH INHIBITORS; MICE; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRIMIDINES; RATS;

EID: 0030799008     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. BERNSTEIN, L. R., ANTONIADES, H. AND ZETTER, B. R.: Migration of cultured vascular cells in response to plasma and platelet-derived factors. J. Cell Sci. 56: 71-82, 1982.
2. BILDER, G. E., KRAWIEC, J. A., ZILBERSTEIN, A., LEVITZKI, A., PERRONE, M. H. AND SCHREIBER, A. B.: Tyrphostins inhibit PDGF-induced DNA synthesis, tyrosine-specific protein kinase activity and c-fos mRNA expression in vascular smooth muscle cells (Abstract). Circulation 82: 571, 1990.
3. BILDER, G. E., KRAWIEC, J. A., MCVETY, K., GAZIT, A., GILON, C., LYALL, R., ZILBERSTEIN, A., LEVITZKI, A., PERRONE, M. H. AND SCHREIBER, A. B.: Tyrphostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells. Am. J. Physiol. 260 (Cell Physiol. 29): C721-C730, 1991.
4. BILDER, G. E., KASIEWSKI, C. J., WALCZAK, E. M. AND PERRONE M. H.: PDGF-receptor protein tyrosine kinase activity in carotid artery is enhanced by injury and inhibited in vivo by tyrphostin RG 13291. Drug Dev. Res. 29: 158-166, 1993.
5. BUCHDUNGER, E., ZIMMERMANN, J., METT, H., MEYER, T., MULLER, M., REGENASS, U. AND LYDON, N. B.: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. U.S.A. 92: 2558-2562, 1995.
6. CALARA, F., AMELI, S., HULTGARDH-NILSSON, A., CERCEK, B., KUPFER, J., HEDIN, U., FORRESTER, J., SHAH, P. K. AND NILSSON, J.: Autocrine induction of DNA synthesis by mechanical injury of cultured smooth muscle cells: Potential role of FGF and PDGF. Arterioscler. Thromb. Vasc. Biol. 16: 187-193, 1996.
7. CLAESSON-WELSH, L.: Platelet-derived growth factor receptor signals. J. Biol. Chem. 269: 32023-32026, 1994.
8. CLOWES, A. W., REIDY, M. A. AND CLOWES, M. M.: Kinetics of cellular proliferation after arterial injury I. Smooth muscle growth in the absence of endothelium. Lab. Invest. 49: 327-333, 1983.
9. CONNOLLY, C. J. C., HAMBY, J. M., SCHROEDER, M. C., LU, G. H., PANEK, R. L., AMAR, A., SHEN, C., KRAKER, A. J. AND DOHERTY, A. M.: Structure-activity relationships of a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase. Book of Abstracts, 211th ACS National Meeting, American Chemical Society, MEDI-193 Publisher, Washington, D.C, March 24-28, 1996.
10. ERPEL, T., ALONSO, G., ROCHE, S. AND COURTNEIDGE, S. A.: The Src SH3 domain is required for DNA synthesis induced by platelet-derived growth factor and epidermal growth factor. J. Biol. Chem. 271: 16807-16812, 1996.
11. FERNS, G. A. A., RAINES, E. W., SPRUGEL, K. H., MOTANI, A. S., REIDY, M. A. AND ROSS, R.: Inhibition of neointimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science 253: 1129-1132, 1991.
12. GOSPODAROWICZ, D., HIRABAYASHI, K., GIGUERE, L. AND TAUBER, J. P.: Factors controlling the proliferative rate, final cell density, and life span of bovine smooth muscle cells in culture. J. Cell Biol. 89: 568-578, 1981.
13. HAWKER, J. R. AND GRANGER, H. J.: Tyrosine kinase inhibitors impair fibroblast growth factor signaling in coronary endothelial cells. Am. J. Physiol. 266: H107-H120, 1994.
14. JACKSON, C. L. AND SCHWARTZ, S. M.: Pharmacology of smooth muscle cell replication. Hypertension 20: 713-736, 1992.
15. JAWIEN, A., BOWEN-POPE, D. F., LINDNER, V., SCHWARTZ, S. M. AND CLOWES, A. W.: Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J. Clin. Invest. 89: 507-511, 1992.
16. KLAGSBRUN, M. AND EDELMAN, E.R.: Biological and biochemical properties of fibroblast growth factors: Implications for the pathogenesis of atherosclerosis. Atherosclerosis 9: 269-278,1989.
17. KLUTCHKO, S., HAMBY, J., BOSCHELLI, D., PANEK, R., LU, G., MAJOR, T., KEISER, J., AMAR, A., SHEN, C., KRAKER, A. AND DOHERTY, A.: Synthesis and structure-activity relationships of a series of 2-substituted-8H-pyrido[2,3-d]pyrimidin-7-one tyrosine kinase inhibitors. Book of Abstracts, XIVth International Symposium on Medicinal Chemistry, p. 11.02, Maasstricht, the Netherlands, September 8-12, 1996.
18. KOVALENKO, M., GAZIT, A., BOHMER, A., RORSMAN, C., RONNSTRAND, L., HELDIN, C. H., WALTENBERGER, J., BOHMER, F. D. AND LEVITZKI, A.: Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 54: 6106-6114, 1994.
19. LEVTTZKI, A. AND GAZIT, A.: Tyrosine kinase inhibition: An approach to drug development. Science. 267: 1782-1788, 1995.
20. LINDNER, V. AND REIDY, M.A.: Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries: An en face study. Circ. Res. 73: 589-595, 1993.
21. LINDNER, V. AND REIDY, M. A.: Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. U.S.A. 88: 3739-3743, 1991.
22. MARX, S. O., JAYARAMAN, T., GO, L. O. AND MARKS, A. R.: Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ. Res. 76: 412-417, 1995.
23. MONTGOMERY, R. B., MOSCATELLO, D. K., WONG, A. J., COOPER, J. A. AND STAHL, W. L.: Differential modulation of mitogen-activated protein (MAP) kinase/ extracellular signal-related kinase kinase and MAP kinase activities by a mutant epidermal growth factor receptor. J. Biol. Chem. 270: 30562-30566, 1996.
24. PELECH, S. AND SANGHERA, J.: MAP kinases: Charting the regulatory pathways. Science 257: 1355-1356, 1992.
25. POSNER, I., ENGEL, M., GAZIT, A. AND LEVITZKI, A.: Kinetics of inhibition by tyrphostins of the tyrosine kinase activity of the epidermal growth factor receptor and analysis by a new computer program. Mol. Pharmacol 45: 673-683, 1993.
26. RAINES, E. W., DOWER, S. K. AND ROSS, R.: Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 243: 393-396, 1989.
27. ROTHMAN, A., WOLNER, B., BUTTON, D. AND TAYLOR, P.: Immediate-early gene expression in response to hypertrophie and proliferative stimuli in Pulmonary arterial smooth muscle cells. J. Biol. Chem. 269: 6399-6404, 1994.
28. ROSS, R.: Polypeptide growth factors and atherosclerosis. Trends Cardiovasc. Med. 1: 277-282, 1991.
29. ROSS, R.: The smooth muscle cell II. Growth of smooth muscle in culture and formation of elastic fibers. J. Cell Biol. 50: 172-186, 1971.
30. SACHINIDIS, A., LOCHER, R., VETTER, W., TATJE, D. AND HOPPE, J.: Differential effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells. J. Biol. Chem. 265: 10238-10243, 1990.
31. SCHOLLMANN, C., GRUGEL, R., TATJE, D., HOPPE, J., FOLKMAN, J., MARME, D. AND WEICH, H. A.: Basic fibroblast growth factor modulates the mitogenic potency of the platelet-derived growth factor (PDGF) isoforms by specific upregulation of the PDGF α receptor in vascular smooth muscle cells. J. Biol. Chem. 267: 18032-18039, 1992.
32. SCHROEDER, M. C., HAMBY, J. M., GROHAR, P. J., WINTERS, R. T., CONNOLLY, C. J. C., SHOWWALTER, H. D. H., KRAKER, A. J., AMAR, A. M., SHEN, C., LU, G. H., DAHRING, T. K., PANEK, R. L., MAJOR, T. C. AND DOHERTY, A. M.: The synthesis and SAR of pyrido[2,3-d]pyrimidine-2,7-diamines in the development of potent water soluble tyrosine kinase inhibitors. Book of Abstracts, 25th ACS National Medicinal Chemistry Symposium, American Chemical Society, poster #14 Publisher, Ann Arbor, MI, June 18-22, 1996.
33. SCHWARTZ, S. M. AND LIAW, L.: Growth control and morphogenesis in the development and pathology of arteries. J. Cardiovasc. Pharmacol. 21: (Suppl. 1), S31-S49, 1993.
34. SHIROTANI, M., YUI, Y. AND KAWAI, C.: Restenosis after coronary angioplastry: Pathogenesis of neointimal thickening initiated by endothelial loss. Endothelium 1: 5-22, 1993.
35. ULLRICH, A. AND SCHLESSINGER, J.: Signal transduction by receptors with tyrosine kinase activity. Cell. 61: 203-212, 1990.
36. WINKLES, J. A. AND GAY, C. G.: Regulated expression of PDGF A-chain mRNA in human saphenous vein smooth muscle cells. Biochem. Biophys. Res. Commun. 180: 519-524, 1991.
37. ZHAN, X., HU, X., FRIESEL, R. AND MACIAG, T.: Long term growth factor exposure and differential tyrosine phosphorylation are required for DNA synthesis in Balb/c 3T3 cells. J. Biol. Chem. 268: 9611-9620, 1993.
38. ZIMMERMANN, J., BUCHDUNGER, E., METT, H., MEYER, T., LYDON, N. B. AND TRAXLER, P.: Phenylamino-pyrimidine (PAP)- derivatives: A new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors. Bioorg. Med. Chem. Lett. 6: 1221-1226, 1996.